文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

利用自然杀伤细胞进行癌症免疫治疗:派遣第一响应者。

Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders.

机构信息

Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA, USA.

出版信息

Nat Rev Drug Discov. 2022 Aug;21(8):559-577. doi: 10.1038/s41573-022-00413-7. Epub 2022 Mar 21.


DOI:10.1038/s41573-022-00413-7
PMID:35314852
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10019065/
Abstract

Natural killer (NK) cells have crucial roles in the innate immunosurveillance of cancer and viral infections. They are 'first responders' that can spontaneously recognize abnormal cells in the body, rapidly eliminate them through focused cytotoxicity mechanisms and potently produce pro-inflammatory cytokines and chemokines that recruit and activate other immune cells to initiate an adaptive response. From the initial discovery of the diverse cell surface receptors on NK cells to the characterization of regulatory events that control their function, our understanding of the basic biology of NK cells has improved dramatically in the past three decades. This advanced knowledge has revealed increased mechanistic complexity, which has opened the doors to the development of a plethora of exciting new therapeutics that can effectively manipulate and target NK cell functional responses, particularly in cancer patients. Here, we summarize the basic mechanisms that regulate NK cell biology, review a wide variety of drugs, cytokines and antibodies currently being developed and used to stimulate NK cell responses, and outline evolving NK cell adoptive transfer approaches to treat cancer.

摘要

自然杀伤 (NK) 细胞在癌症和病毒感染的先天免疫监测中起着至关重要的作用。它们是“急救员”,可以自发识别体内的异常细胞,通过集中的细胞毒性机制迅速消除它们,并有效地产生促炎细胞因子和趋化因子,招募和激活其他免疫细胞以启动适应性反应。从最初发现 NK 细胞表面的多种受体,到描述控制其功能的调节事件,我们对 NK 细胞基础生物学的理解在过去三十年中得到了显著提高。这一先进的知识揭示了更复杂的机制,为开发大量令人兴奋的新疗法打开了大门,这些疗法可以有效地操纵和靶向 NK 细胞的功能反应,特别是在癌症患者中。在这里,我们总结了调节 NK 细胞生物学的基本机制,回顾了目前正在开发和使用的各种药物、细胞因子和抗体,以刺激 NK 细胞的反应,并概述了不断发展的 NK 细胞过继转移方法来治疗癌症。

相似文献

[1]
Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders.

Nat Rev Drug Discov. 2022-8

[2]
Natural killer cell biology: an update and future directions.

J Allergy Clin Immunol. 2013-7-30

[3]
Natural killer cells and cancer therapy, what we know and where we are going.

Immunotherapy. 2019-8-19

[4]
Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy.

Front Immunol. 2023

[5]
Natural killer cells: the journey from puzzles in biology to treatment of cancer.

Cancer Lett. 2015-2-28

[6]
Natural killer cell-based strategies for immunotherapy of cancer.

Adv Protein Chem Struct Biol. 2022

[7]
Exploring the NK cell platform for cancer immunotherapy.

Nat Rev Clin Oncol. 2021-2

[8]
Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.

Front Immunol. 2021

[9]
[Natural killer (NK) cell and immunotherapy].

Nihon Rinsho. 2017-2

[10]
Harnessing adaptive natural killer cells in cancer immunotherapy.

Mol Oncol. 2015-12

引用本文的文献

[1]
ADAR1 expression is associated with cervical cancer progression and negatively regulates NK cell activity.

JCI Insight. 2025-7-8

[2]
Recent advances and challenges of cellular immunotherapies in lung cancer treatment.

Exp Hematol Oncol. 2025-7-7

[3]
Emerging roles of KIR2DL4 in cancer immunotherapy.

Breast Cancer. 2025-6-23

[4]
Impaired natural killer cell maturation in lung adenocarcinoma driven by and downregulation through disrupted lipid metabolism.

Transl Lung Cancer Res. 2025-5-30

[5]
Novel strategies to overcome tumor immunotherapy resistance using CAR NK cells.

Front Immunol. 2025-5-29

[6]
Enhancing radiotherapy-induced anti-tumor immunity via nanoparticle-mediated STING agonist synergy.

Mol Cancer. 2025-6-11

[7]
Analysis of the differences in immune indexes of common gene mutations and 5q- chromosome karyotype mutations in MDS.

Discov Oncol. 2025-6-9

[8]
Identification of a JAK-STAT-miR155HG positive feedback loop in regulating natural killer (NK) cells proliferation and effector functions.

Acta Pharm Sin B. 2025-4

[9]
The potential role of biomarkers CD28 and PF4 in the pathogenesis of idiopathic pulmonary fibrosis and their impact on the prognosis: an immune microenvironment analysis.

Hereditas. 2025-6-7

[10]
Transitioning from native to synthetic receptors: broadening T-cell engineering and beyond.

Cell Mol Immunol. 2025-6-6

本文引用的文献

[1]
Resistance to natural killer cell immunosurveillance confers a selective advantage to polyclonal metastasis.

Nat Cancer. 2020-7

[2]
A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial.

Eur J Cancer. 2021-10-9

[3]
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.

Lancet Oncol. 2021-6

[4]
Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30 Malignancies.

Clin Cancer Res. 2021-7-1

[5]
Metabolic flexibility determines human NK cell functional fate in the tumor microenvironment.

Cell Metab. 2021-6-1

[6]
Expansions of adaptive-like NK cells with a tissue-resident phenotype in human lung and blood.

Proc Natl Acad Sci U S A. 2021-3-16

[7]
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.

Front Immunol. 2021

[8]
Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation.

Blood Adv. 2021-2-23

[9]
Exosome Surface Display of IL12 Results in Tumor-Retained Pharmacology with Superior Potency and Limited Systemic Exposure Compared with Recombinant IL12.

Mol Cancer Ther. 2021-3

[10]
ADCC against MICA/B Is Mediated against Differentiated Oral and Pancreatic and Not Stem-Like/Poorly Differentiated Tumors by the NK Cells; Loss in Cancer Patients due to Down-Modulation of CD16 Receptor.

Cancers (Basel). 2021-1-11

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索